FDA Approves Migraine Drug For Pediatric Patients

From NeurologyWire

FDA has approved Treximet (sumatriptan and naproxen sodium) for use in pediatric patients 12 years of age and older for the acute treatment of migraine with or without aura.It is the first approved combination prescription medicine, and the first to contain sumatriptan, for the treatment of acute migraine attacks in pediatric patients. The two medi...

Login to read story

Thursday, July 23, 2015

Show last days of articles

American Parkinson Disease Association Awards $1.3m In Resea...

From NeurologyWire

The American Parkinson Disease Association is pleased to award $1.3 million for 2015-2016 research funding to support four Post-Doctoral Fellowships, ...Full story

MS Patients with Sleep Disorders Have Reduced Quality of Lif...

From NeurologyWire

MS patients with sleep disordersespecially those with OSA or insomniahave reduced quality of life (QoL), compared with those without sleep disorders, ...Full story

Wednesday, July 22, 2015

Cancer Associated With Unfavorable Survival in Stroke Patien...

From NeurologyWire

Cancer, especially active cancer and no other apparent cause for stroke, is associated with unfavorable survival among young stroke patients, accordin...Full story

Tuesday, July 21, 2015

Football Conference Adding Medical Observers For Games

From NeurologyWire

The Atlantic Coast Conference will deploy "medical observers" to its college football games this fall, according to conference commissioner John Swoff...Full story

Monday, July 20, 2015

American Headache Society Urges Patients, Physicians to Heed...

From NeurologyWire

In follow-up to the FDA's warning on NSAIDs risks , an educational initiative is underway by The American Headache Society to be sure people with migr...Full story

Thursday, July 16, 2015

Alzheimers May Affect the Brain Differently in African-Ameri...

From NeurologyWire

Alzheimers disease may cause different changes in the brain in African-Americans than in white Americans of European descent, according to a study pub...Full story

Wireless System to Assess Spinal Cord Stimulation Prior to S...

From NeurologyWire

FDA has approved the St. Jude Medical Invisible Trial System, a neuromodulation programming system designed to help chronic pain patients better asses...Full story

Wednesday, July 15, 2015

Study Confirms Lacosamide as Add-on Therapy for Epilepsy

From NeurologyWire

Lacosamide is effective and fairly well tolerated in the short-term when used as add-on treatment for drug-resistant partial epilepsy in adults, accor...Full story

Tuesday, July 14, 2015

FDA Approves Rexulti (brexpiprazole) for Depression, Schizop...

From NeurologyWire

FDA has approved Rexulti (brexpiprazole) as an adjunctive therapy for the treatment of adults with major depressive disorder (MDD) and as a treatment ...Full story

Monday, July 13, 2015

Changes in Alzheimers Biomarkers During Midlife May Predict ...

From NeurologyWire

Scientists have shown that changes in key biomarkers of Alzheimers disease during midlife may help identify those who will develop dementia years late...Full story

Friday, July 10, 2015

Teva Takes Migraine Drug Generic

From NeurologyWire

Teva Pharmaceutical Industries will be the first in the US to launch a generic form of the migraine drug Axert (almotriptan malate) tablets. The table...Full story

Study Shows Long-Term Effects of Type 2 Diabetes on the Brai...

From NeurologyWire

In a matter of two years, people with type 2 diabetes experienced reduced ability to regulate blood flow in the brain, which was associated with lower...Full story

Thursday, July 09, 2015

FDA Strengthens Warning of Heart Attack and Stroke Risk for ...

From NeurologyWire

FDA is strengthening an existing warning in prescription drug labels and over-the-counter (OTC) Drug Facts labels to indicate that nonsteroidal anti-i...Full story

Allergan Buys Rights to Merck's Migraine Drugs

From NeurologyWire

Perhaps the most exciting advance in the migraine pipeline is the development of calcitonin gene-related peptide (CGRP) receptor antagonists, and Alle...Full story

Tuesday, July 07, 2015

Horizon Launches Hostile $3-billion Bid of Depomed

From NeurologyWire

Horizon Pharma said Tuesday it is proposing to acquire all outstanding shares of Depomed at $29.25 per share, in an all-stock deal worth roughly $3 bi...Full story